Abstract library

9 results for "Barnes".
#174 Loss of Expression of the DNA Mismatch Repair Proteins MLH1 and MSH2 is Rare in Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: Loss of expression of the DNA mismatch repair (MMR) proteins MLH1 and MSH2, which is known to correlate strongly with MSI, has not been well studied in pancreatic or small intestinal NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Daniel Rayson
Authors: Rayson D, Arnason T, Sapp H, Barnes P, ...
#175 The Immunohistochemical (IHC) Expression and Prognostic Value of ER, PR, and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: There has been limited study of ER and PR expression in gastrointestinal neuroendocrine tumors (GINETs) and data on HER2/neu overexpression in GINETS has been conflicting.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Daniel Rayson
#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET
Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
#1309 Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET)
Introduction: 68Ga-DOTATATE (DOTA) and FDG PET have been utilised in NETs to aid diagnosis, prognostication and guide management. FDG PET avidity is associated with poor prognosis, but the prognostic significance of dual FDG/DOTA grading has not been explored.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr David Chan
Authors: Chan D, Bailey D, Schembri G, Bernard E, ...
Keywords: PET, prognosis
#1311 Blood-Based Prognostic Biomarkers in Neuroendocrine Tumour: A Retrospective Study
Introduction: Markers of systemic inflammation –such as the neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR) and lymphocyte:monocyte ratio (LMR) - have been shown to correlate with poor prognosis in multiple solid organ tumours. Analysis of CLARINET showed no significant association between NLR and progression-free survival.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr David Chan
Authors: Diakos C, Chan D, Gurney E, Bailey D, ...
Keywords: NLR, biomarker
#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience
Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: everolimus SSA
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.